A Phase 3b, Multi-center, Open-label, Trial to Evaluate the Long Term Safety of Titrated Immediate -release Tolvaptan (OPC 41061,30mg to 120mg/day, Split-dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease
Along with his co-authors — including former trainees in
the Department of Orthopaedics — Leslie J.
Bisson, MD, has won an award from the Orthopaedic Journal of
Sports Medicine for authoring the “most outstanding
clinical paper” to appear in the publication in 2016.